Good day ladies and gentlemen and welcome to the Jazz Pharmaceuticals Second Quarter 2014 Earnings Conference Call. Following an introduction from the company, we will open the call to questions. I'll now turn the call over to Kathy Littrell, Head of Investor Relations at Jazz Pharmaceuticals.

Thank you, Sara and thanks each of you for joining our Investor call. Today, we reported our second quarter financial results and updated our 2014 financial guidance in the press release. The release and the slide presentation accompanying this call are available on the News & Events section of our website. With me for today's call are Bruce Cozadd, CEO; Matt Young, CFO; Russ Cox, CCO; Jeff Tobias, CMO and Mike Miller, Head of U.S. Commercial. Following some remarks, we'll open the call for your questions. I'd like to remind you that some of the statements we will make on this call relate to future events and our future performance rather than historical facts and are forward-looking statements. These statements include future financial results and commercial development and regulatory plans, expectations and projections and the potential timing of future events. Examples of forward-looking statements include our 2014 financial guidance; anticipated growth prospects for our products; planned commercial efforts, including the rolling launch of Defitelio in Europe; and related pricing and reimbursement approvals expected and potential interactions with regulatory agencies regarding Xyrem and other products and product candidates; anticipated regulatory submissions, anticipated litigation-related events and the timing thereof, and the timing and other matters related to planned and ongoing trials, including enrollment in and results from and cost associated with those critical trials. These forward-looking statements involve numerous risks and uncertainties that could cause actual results, performance and results to differ materially. These risks and uncertainties are identified and described in today's press release, the slide presentation accompanying this call and under risk factors in our Form 10-Q for the year ended March 31, 2014, and our Form 10-Q for the quarter ended June 30th, 2014, that we expect to file shortly. We undertake no duty or obligation to update any forward-looking statements we make today. On this call, we will discuss several non-GAAP financial measures, including historical and expected 2014 adjusted net income attributable to Jazz and the related per share measures and historical and expected 2014 adjusted SG&A and R&D expenses. We believe that these non-GAAP financial measures are helpful in understanding our past financial performance and potential future results. They are not meant to be considered in isolation or as a substitute for comparable reported GAAP measures. Reconciliation of GAAP to non-GAAP financial measures discussed on this call are included in today's press release and the slide presentation accompanying this call. Both are posted in the News & Events section of our website. I'll now turn the call over to Bruce.

Good afternoon everyone and thank you for joining us. We're pleased with our strong performance in the second quarter and the significant progress we have made year-to-date. This year we acquired Gentium and commenced our launch of Defitelio in European Union, acquired the rights of defibrotide in the U.S. and the rest of the Americas from Sigma-Tau and a transaction that closed yesterday, schedule two pre-NDA meetings with FDA in the third quarter to further our understanding of the regulatory pathway forward for defibrotide in the U.S., acquired rights to JZP-110, presented JZP-110 phase IIb data at the 2014 SLEEP meeting in June, met with the FDA and defined our phase II program for JZP-110 and received notification of issuance of the new patent related to Xyrem with an expiry in 2033. Our financial performance in the second quarter included revenues of $291 million, up 40% compared to the second quarter of 2013 driven by increased sales of our key products Xyrem, Erwinaze and addition of sales of Defitelio. We realized adjusted net income attributable to Jazz of $128 million in the second quarter, reflecting the attractive margins in our business. GAAP income attributable to Jazz for the quarter was $44 million. I will now update on our SLEEP and hematology/oncology franchises, including information on key commercial, legal, regulatory and clinical development activity during the quarter and then end my section with a few comments about our new board member and the new members of the senior management team at Jazz. Matt will then review our financial results for the quarter and provide comments on our guidance. I will start my comments with our SLEEP franchise and our lead product Xyrem. through the acquisition of rights to our new product candidate, JZP-110, which joins JZP-386 in our R&D pipeline, as…

Thanks, Bruce, and good afternoon everyone. We're pleased with our strong performance in the second quarter as we saw adjusted EPS attributable to Jazz increased by 43% year-over-year. We expect continued strong topline growth for 2014 driven by growth in the sales of Xyrem, Erwinaze and Defitelio. We're increasing our total revenue guidance to be in the range of $1.125 billion to $1.165 billion and maintaining our adjusted EPS guidance to be in the range of $8 to $8.25. Net sales of Xyrem for the quarter were $191 million, up 43% from $134 million in the second quarter last year. We're increasing our guidance for Xyrem net product sales to a range of $765 million to $780 million for 2014 based on three factors; improvement in bottle volume growth during Q2 to the low double-digits versus mid-single-digit growth during the first quarter, a price increase of 8% on August 1st, and improving gross to net resulting from lower than expected coupon utilization. We continue to expect high single to low double-digit bottom volume growth in 2014. Turning to Erwinaze. Second quarter worldwide net sales were $48 million, up 7% from the same period in 2013. We're reaffirming our guidance for Erinaze net product sales in the range of $185 million to $200 million for 2014. This reflects a 3% price increase in the U.S. in early July. For Defitelio/defibrotide, second quarter worldwide net sales were $20 million compared to pro forma net product sales of $10 million in the second quarter of 2013. During the second quarter, sales benefited from an increase in shipments to distributors. In early July, we made the decision to discontinue the cost recovery program in the U.S. so that patients in the expanded access program will now receive free drugs. As you know the U.S.…

Thanks Matt. (Operator Instructions) With that said I will turn the call back to the operator to open the lines for your questions.

(Operator Instructions) our first question comes from Louise Chen from Guggenheim.

Hi, thanks for taking my questions. My two questions are. First one is on your capacity to do another M&A deal before the end of the year. Is that something that we could potentially look forward to? And then secondly, how should we think about R&D cost for 2015. You had mentioned $100 million in clinical trial cost for JZP-110 in 2015, 2016. Wondering what else should we think about and how should we think to grow it year-over-year between 2014 and 2016? Thanks.

Thanks Louise. With respect to corporate development, as we've often articulated, we will continue to be active. We are happy that we've been able to complete three transactions this year so far and excited about continuing to build on the already well-established team here. That said, as you know, difficult for us to predict the timing of when we will actually get a transaction done. We remain proactive and we continue to believe we see a significant number of opportunities both in our existing business areas and beyond that. So we will keep at it and hopefully be able to do something. But we can't say exactly when. With respect to R&D expenses, we've specifically talked about the cost of the overall JZP-110 program being consistent with our previous comments in the neighborhood of $100 million. The majority of that spend being in 2015 and 2016. We do expect overall R&D expenditure as a percentage of sales and in dollar terms to go up. But we again provide guidance just for 2014, so while we expect the guidance range we set this year, I think with other programs maturing across our sleep and hematology franchises with respect to both new products and lifecycle management, we would anticipate some rise in R&D expenses going forward.

All right. Our next question comes from David Amsellem from Piper Jaffray.

Thanks for taking the questions. So my two as follows. So, first, I guess you sounded a little bit cautious on the Central Pharmacy issues going forward. I guess, maybe I'm reading too much into the commentary, but is there a risk that there could be bottlenecks again regarding the Central Pharmacy on Xyrem. And then the second question is on Defitelio, at the risk of putting the cart before the horse, I just wanted to get a sense of how you would think about pricing in the U.S.? Maybe give us a sort of a set of benchmark comparative products if you will, or just help us think about pricing vis-à-vis Europe? Thanks.

Thanks David for the questions. On SES you know the caution in my voice, I think we will go right back to the comment I made on the first quarter call when I think Russ and Mike also made, which is, our goal is to get to a point where we are on top of our current operations, the metrics are all good. But we also feel confident that we won't see a recurrence of problems. Another words that we build in surge capacity and flexibility to deal with any issues that arise in the future. And while I think we are pleased with the progress that been made over the last several months and I think you certainly saw that -- the pull through of the demand we've been generating in the second quarter was good. I think a couple of months' performance is too short of us to be able to say problem definitely in the rearview mirror. So I don’t mean to sound overly cautious other than this to us was not just a couple of month exercise, this is really about building excellence in terms of how we service patients and physicians that we have high confidence in the for the long-term. On your second question, Defitelio pricing in the U.S., I think it's probably too early for us to be commenting on that. as I said our real focus right now is defining a regulatory pathway and seeing if there is an opportunity to get this in the hands of physicians and patients sooner rather than later.

All right. Our next question comes from Marc Goodman from UBS.

Bruce, maybe you can talk about Defitelio and the pricing in Europe and just as these conversations are having and you rolling out, you mentioned some of the Nordic countries. So how is pricing there. How should we think about the pricing in Italy now versus what it will be and how Ireland, Netherlands are. Are all these prices generally the same or relative to where you are? And then just on Xyrem, can you talk about these eight cities that you've rolled this program out into. Are you seeing sales yet, I understand the metrics that you were talking about before. How much lead-time on the sales and are we going to see those sales? And then just I understand, just as a follow-up kind to previous question on this quarter, I mean, there was a lot of nervousness, obviously going into this quarter because of what happened with the call center. So did the call center just work as we thought this quarter? I mean, everything was just ticking along, because obviously the volume growth was generally in line with that we would have expected even last quarter?

Yeah. So trying to figure out how that was two questions, Marc, but you are good. So pricing in Europe, I think we will try to avoid going literally country by country in our commentary. But in general, I would say we have been pleased by the responses we've had to our pricing and reimbursement submission relative to our expectations when we announced and closed the Gentium transaction earlier this year. Russ, do you want to add anything on that before going to the other questions.

Yeah, would just say that, if you look at where we are referenced in Germany and Austria at €426, I mean, that was a good basis point to start. And then as new countries come on line we will continue to give information as we go.

Yeah, on the disease awareness initiatives for narcolepsy, the real goal there is to make a dent in a very large undiagnosed narcolepsy population, which in the U.S. is estimated to be larger than the currently diagnosed and treated market and we know that patients do go years before they get to the right diagnosis. There is still some time that happens between a diagnosis and treatment and treatment can include, but is not limited to Xyrem. So in terms of seeing a flow-through to sales, that's not something we are expecting in the near term. But obviously we would love to over time see a larger pool of patients being treated for their disease. On the comment about nervousness, you know, I understand there may have been some nervousness out there. If you go back to our comments in the first quarter, I think we were pretty clear that we reiterated our Xyrem guidance for the year. We said we obviously couldn’t undo the first quarter and get that business back, but that we were pretty confident about our business going forward. We are pleased to see that that confidence was, you know, well placed in terms of our second quarter reported results. And we don’t the rest of the year for granted either, we got to get out there and do our jobs every day. But I wouldn’t say around our table there was nervousness. There was honestly disappointment in ourselves and in the central pharmacy that we didn’t do what we were supposed to do which is make sure that those prescriptions are timely filled or refilled. And we obviously took that seriously and wanted to do everything we could to fix that as quickly and as well as we could.

All right. Great. Our next question comes from Michael Faerm from Wells Fargo.

Thanks for taking the question. I have two. First one on M&A, your deals are generally showing a consistency in terms of being orphan or orphan like products and all the commercial characteristics that come with that. I am wondering to what extent you would be willing to look at things that are outside that range of characteristics that you have looked at so far whether it’s commercially or in terms of size of deal. And then my second question is on Xyrem pricing. You have taken your second increase this year. I just wonder as we look out down the road, as the product gets bigger, how do you feel about your flexibility to continue to take the types of increases that you have been taking? Thank you.

Okay. Mike, on your first question, in terms of the consistency of the types of transactions we have done, I don’t think we necessarily define our target opportunity space as being a solely limited to orphan. We defiantly look for products that make a significant difference to the patients who used them that are differentiated that have good exclusivity. But the other thing we are specifically looking for are that those patients would be treated by a specialists group of physicians that we could target with an efficient sales force. So in many ways our lens that were sorting opportunities through has more to do with the effectiveness of our commercial activities rather than just a count of raw number of patients out there. It’s some combination of the number of patients out there and how efficiently we can get to those patients. Matt, anything else do you want to add on our targeting?

No, I think that it, Bruce.

And then the second part of the question on price increase, maybe I will hand over to Mike.

. :

All right. Our next question comes from Jason Gerberry from Leerink Partners.

Hi. Thanks for taking the question. First, just could you guys comment at all exactly with respect to Xyrem legal regulator front, what level of the FDA you are currently submitting your appeal and how many appeals do you think you have with the agency figured I'd give that one shot. And then secondly on Defitelio, can you just comment on the quarter to the extent there was any launch stocking as I look at the second half what's implied by the guidance, it looks like a little bit of a slowdown relative to the 2Q run rate, and I am just wondering ahead of few country launches wider might be. Thanks.

Yeah, Jason, on formal dispute resolution process with FDA, our initial formal dispute resolution filing went back to the people who had made the original decision with respect to our deemed REMS to final REMS conversion. We are now at sort of the level, up from that. There are several potential layers above this. A little too early for us to say what will happen, it very much depends on the response we get FDA and it depends on who at FDA has been actively involved in responses we do get. But I think we have been pretty consistent in our commentary that we sort of thought we needed to get at least one level up within FDA before we get a different set of eyes looking at the issues that we think are very important to patient and public safety. On the Defitelio guidance and what that implies about second half versus first half, maybe I will have Russ comment on that.

Yeah, I would just comment that I wouldn’t look this as really stocking per se. I would think of this as -- thinking about as countries come online and ultimately determining the timing when they go from an inpatient program actually to a foreign launch and just building in the modeling to be conservative there. So I think that if you think about how those respective countries come online reflecting the timing of that.

Okay. Thank you.

That's said, I do think we had a couple of distribution partners in markets. We are not commercializing indirectly ourselves to add some orders filled during the second quarter and a little uncertain on our part is to how quickly those orders would recur.

Got it. Thank you.

Thank you. Our next question comes from Oren Livnat from JMP Securities.

Thanks, guys. A tremendous quarter. If I could just shift to the pipeline a little bit. You know, I have conversions around JZP-110 and there is seems to be a pretty big disconnect out there about if successful where you see the thing potentially positioned. Can you may be help us frame it on the spectrum on one end competing directly with Provigil new visual at somewhat comparable brand pricing with better efficacy. And at the other end you have got a Xyrem lifecycle extension and there is obviously a lot of room in between with regards to pricing and improve your targeting. So can you may be help us understand what you envision this high being?

Yeah, Oren thanks for the question. In terms of how we think about JZP-110, a couple of comments. The first is as we have described the market opportunity to you and in some of the slides that we have shown historically, you will note that we will start by looking at those patients with narcolepsy or OSA who experienced successive daytime sleepiness that is not adequately addressed by other available agents. So we haven’t done our phase III, we haven’t got a regulatory approval. We are not out there selling the product, so there is lots of time between here and there. But I would say, in general, we are looking at addressing a patient population that is enable to tolerate or doesn’t get adequate efficacy from the other agents rather than necessarily going right at them for competing to get the patients in the first instance. To the sort of second part of your question, we don’t see this is a Xyrem lifecycle management opportunity. Xyrem obviously has a different indication for the treatment of cataplexy and DDS in narcolepsy patients. And you probably remember that the majority of Xyrem patients are certainly in our clinical trials also do take a stimulant as well. So they are taking Xyrem at night and then they are taking stimulants during the day and getting additive benefit of those two agents. So I wouldn’t think of JZP-110 in the same category as Xyrem.

I can just follow-up with a simple tax rate question too. I think the last time -- I could be mistaken, I think the last time we heard from you guys on guidance for this year were maybe high teens similar to 2013. I think you're trending for the first couple quarters slightly ahead of last year, I'm just wondering going forward through the rest of the year where you see it shaking out and what's the trend directionality look like?

Thanks. With respect to our cash ETR, I would expect still high teens is the right thing to think about Warren. We have seen it turned up slightly with respect to basically mix where that occurred geographically what products and then also was somewhat R&D expenses had pushed the tax rate of slightly, but we don't anticipate a significant deviation from where we are.

Thank you.

Our next question comes from Gregg Gilbert from Deutsche Bank.

Thank you. I have two. First on JZP-110, I don't know when we're going to see the final details of trials design, but maybe you could share some of the goals you are trying to achieve in Phase III that go beyond simple approvability in light of the particularly robust results that we're seeing in Phase II. And my second question for Bruce or Matt is on BD your strategy has been well articulated, my question is whether or not you're seeing any possible deals that would materially diversify your cash flows in one fell swoop while still honoring your core criteria that you've laid out. Thanks.

Okay, Gregg let me have Jeff take your first question on goals of the Phase II program for JZP-110.

Right. So for JZP-110, you're right to point out that there are the approvable endpoints which Bruce has already talked about objective and WT and subjective for sleepiness scale. But we certainly intend to look at other potential outcomes or beneficial outcomes that would add to the overall profile of the product. And we have a few things that we're exploring right now the might be pretty interesting some of which is not have been done before. But as we start finalizing these protocols, we'll share more of that but as certainly part of our thinking with the trial moving forward.

And I'll let Matt take your second question.

Yeah. Thanks Gregg. I'd say as we said before we're certainly willing to consider transactions from the business development perspective that are very big or continue the strategy of some smaller deals. I think one large transaction that might immediately diversify us is one solution to a particular objective. We believe through the course of again doing three deals this year adding some development programs the sales of which can also be a substantial diversification of our revenue and add to our growth in the out years is also an important strategy. So, we're going to continue to look at all of those things and so we obviously can't comment on any specific activity but certainly any and all of that is on the table for us.

Thank you.

Our next question comes from Ken Cacciatore from Cowen & Co. Ken Cacciatore - Cowen & Co.: Hi guys thanks. I had a question on the (Flamel) [ph] sodium oxybate reformulation, just want to know if this progresses through the clinic, would they need to eventually certify to your distribution patents? At what point would they need to do that? And at what point could you enter into litigation to maybe an act of 30 months stay, would you have to wait for an approval and so could your patents end up tying them up well beyond any timeframe in which you're working on your reformulation? And then secondly on the discussion around BD, just wondering as we go forward here, has there been any change in the value of potential assets, are they becoming more expensive less just a little bit of commentary on what you're seeing around valuation as you look at potential acquisitions? Thank you.

Yeah Ken in terms of your first question, I don't think we're going to comment on other people's products or programs specifically. I will say anyone wanting to either end the Xyrem or 505(b)(2) Xyrem data is going to need to certify to all Orange Book-listed patents. That's just the way it works. And yes, we would have the opportunity to litigate if there's a basis for litigation and yes, that would trigger a 30-month stay. On the second part asset values and how their changing maybe I'll have Matt comment on that.

Sure. Thanks Ken. With respect to asset values, we continue to see opportunities out there that we proactively have been evaluating where hopefully value and risk align. I think there's always more than the dimension of value when you're looking at various product opportunities or product development opportunities. That said and certain spaces with a very well-characterized and understood asset in the public domain, it certainly, in some cases, has been fully valued and I think you and others have commented on that. But there are always opportunities where that isn't the case from our point of view and that's why we say it's very difficult for us to predict the timing associated with trying to get a transaction done for what we're looking. But we continue to believe again that value and risk will align and we'll be able to continue to pursue activities that will bring new products. Ken Cacciatore - Cowen & Co.: Thank you.

Our next question comes from David Buck from Buckingham Research Group.

Yeah. Thanks for taking the questions. Just a couple quick ones. For Xyrem if we look at the 11% volume growth that you saw in the second quarter, how much of that would you say is potentially some catch-up from law sales in the first quarter and would you expect to sustain that type of level of growth at least for this quarter or somewhere -- somewhat less? Secondly on the Erwinaze product growth is a little bit slower year-over-year, can you touch base on whether there's anything in the inventory supply that affected the quarter? And then finally just to clarify on the answer to the question on 505(b)(2) applications. My understanding is the gating factor is basically a filing of the 505(b)(2) that would lead to certification is that true? And that's it thanks.

Yes, I'll take that last one first David. I think I didn't fully answer Ken's question, so thanks for giving me that opportunity. Yes, that's a trigger for litigation, not product approval correct. On the Xyrem question on volumes, I think as we said at the end of the first quarter on our call, we can't really go back and recapture lost volume for the first quarter meaning that a patient who didn't receive a timely refill and went without drug for a week doesn't take twice as much drug the next week and shouldn't if any patients are listening. So, there's no catch-up in that sense. Were we coming out of it period where shipments were low? Where we had some higher shipment days coming into the quarter? Maybe, there could be a little bit of that, but essentially what you saw in the second quarter was our shipment volumes very closely tracking the growth in patients and underlying demand. What exactly that means for the second half? I can't tell you anything more than the guidance we've given you in terms of Xyrem revenues and the guidance that we expect full year volume growth will be high single or low double-digit. So, that probably is enough on that one. On Erwinaze I think we've tried to condition people over the course of the past seven or eight quarters that percentage growth in Erwinaze tends to be pretty lumpy. We're talking about a very small number of patients being treated with the disease. I don't think there's a meaningful "inventory affect" with this product. Again some of our international Erwinaze sales do go through distributors and there's different timing of shipments, but we don't really see much of an impact on that on the total reported sales.

Our next question comes from Gary Nachman from Goldman Sachs.

Hi. Bruce could you talk about the increase call volume at STS and getting Xyrem filled, does that change at all or is it starting to come down? It seems like you're managing the process better, but I'm curious on the actual volumes if that's changed. And then secondly where exactly is the additional R&D spend going this year? It seems that more about heavy the spending really hits next year and you guys took up the revenue guidance, but not EPS, so I'm curious if that's just you guys being conservative? Thanks.

Yeah, let me take the second question and I'll have Mike comment on the call volume at STS. We took up the R&D spend guidance in part for a structural reason, which is we just closed a transaction with Sigma-Tau concerning defibrotide. And prior to that transaction closing, Sigma-Tau was sharing development expenses with respect to defibrotide with us. So a piece of what you are seeing in the changed guidance is just we are on the hook for 100% rather than 50% of that spend. In terms of where we are spending the money. We are in clinical trials we were in last year and getting ready to initiate clinical trials end of this year, early next year that are new for us. So the level of activity has gone up substantially. Remember JZP-110 was a transaction we closed in January of this year and if you look at the range of clinical activities we have across getting started on the pediatric side with narcolepsy with Xyrem as well as JZP-110 and then what we are doing with Erwinaze in the young adult population as well as the follow on JZP-416 and the defibrotide and a registry trial with PRIALT. There is just a lot more activity than there was last year. Mike, maybe you could talk about call volume at STS?

Sure, Bruce. On the call volume, remember that Q1 had sort of a constellation of event, you had the Affordable Care Act, you had people reupping in terms of the seasonality of the year and weather. And when service levels began to falter that actually generated more calls. And what we've seen in Q2 has been a step up in all operational metrics including timely fills, refills, answering the phone, drops in abandonment, things of that nature. So we are very pleased around the operational metrics and it's not necessarily the call volume but how the operational metrics are actually directionally heading, and we are very pleased with the way they are heading.

Okay. Thank you.

Our next question comes from Annabel Samimy from Stifel.

Hi, thanks for taking my question. I have a couple. First on JZP-386, I was glad to see just initiated Phase I studies. Can you give us an idea of when you expect to see some data from that and what you are looking for in terms of determining whether you can move straight into Phase III? And then regarding the Xyrem patent, I seems like its bit of a carve out of the population who takes asparaginase. So what percentage of the population actually takes that and can you carve out something and was that the pattern that you are waiting for? Is there an additional family of patents that you are still waiting for? Thank you.

So let me have Jeff the take first part of your, which is expectations for what we are looking for in the 386 data.

Right. So just a recap. We have initiated the trial. We expect it to conclude this year. We will be working with concert in the evaluation of those data. It's not as straight forward, although we have certain criteria we expect to see in the performance of the product. There are lot of different pieces you need to look at just not just decay, but also PD issues. And looking forward what would provide the potential for a product that could have once-nightly dosing, now have too long of half-life because you don’t want it lasting all day long. And then something that could be evaluated in additional study. There's still fair amount of work to be done and certainly evaluation of the data once it's available to us.

And then Annabel on the second part of your question on the use of Xyrem and valproate together, we certainly know what happens. It's not uncommon. We don’t have perfect data on every script that’s filled on that if we can -- that we can give out. But it is important in that population to recognize the interaction between the drugs and lower the dose of Xyrem and I think for safety reasons that’s important for these patients. So we do believe that’s important information for them and their treaters. And then is there another family of patents out there, we are not going to comment on that specifically. But I will say, you notice that this one had an expiration date later than the 2024 date. But it previous been our latest to expire patent and we certainly had told people that there patents working there through the system that could have new expiration dates beyond 2024. This certainly is such a patent. We continue to have additional Xyrem related patents working their way through the PTO. I can't say with the confidence exactly when they will issue or if they will issue. But there are others in process.

Thank you.

All right. Our next question comes from Douglas Tsao from Barclays.

Hi, good afternoon. Bruce maybe looking on the hematology/oncology franchise, if could talk little bit about Asparec and how you see that sort of change the dynamic for your -- for the ALL franchise?

Yeah, so Doug, on JZP-416, a couple of things about that product that we think are interesting. One, from a patient is, it’s a PEGylated product which we believe would offer the opportunity for less frequent dosing. So Erwinaze given I'm or even given IV, which it is in Europe on label and of course we have a PDUFA date at the very end of this year on potential for IVs in the U.S. Its dosed Monday, Wednesday, Friday, Monday, Wednesday, Friday. JZP-416 would offer the possibility of less frequent administration and more convenience to patients. Beyond improvements that would be visible to patients, we also like the fact that the recombinant production technology might give us a means to a more flexible supply chain. We've highlighted that historically we are somewhat capacity constrained with respect to Erwinaze production and this would have a meaningful difference on production. So obviously needs to get through the trials and get something to FDA and European regulators to consider. But we view this as being a potentially a very good product for the patients with ALL.

And do you see the potential opportunity because given the dosing advantages of Oncaspar, do you see this as potentially sort of moving Asparec up in terms of the treatment, the sort of E. coli derived asparaginase sort of moving up in the treatment paradigm?

Yeah, it's conceivable. But I've been cautious to tell people that unless we saw a meaningful advantage to JZP-416 to patients, our expectation is that physicians would go with E. coli derived asparaginase that Scott, more history more data and reserve the Erwinia derived asparaginase for those patients who can't tolerate or develop a hypersensitivity reaction to the E. coli asparaginase. So it's not completely out of the question. But we are certainly not trying to guide people to expect that it would move up in the treatment paradigm.

Okay. And then if I can jump in with one final question on Erwinaze. As you said, sort of growth is potentially a little lumpy, I know you sort of went through a period where you had some initial initiatives that sort of really reaped the lot of benefits in terms of volume improvements. Are we sort of now waiting for some of the data in the AYA population to mature before we sort of see another step up in growth rates there?

I would say something that I've said before. So it's not intended to be new information. But I sort of feel as though we've penetrated the pediatric hypersensitivity opportunity fairly well, that’s not to say there is not potential growth left there. But we've made great strides in making sure that most of the centers that would logically use the product are aware of how to use it, when to use it. I think we still have some work to do on educating treaters on appropriately recognizing hypersensitivity reactions and knowing when to use the product. But we think we've made great strides in the pediatric hypersensitivity opportunity. The other growth opportunities we see including the adolescent young adult population and the potential for greater use of therapeutic drug monitoring are essentially changes in behavior. That’s not the way things are done now. And predicting when changes in behavior will occur is a little bit trickier from our perspective. So I think there is that growth opportunity out in front of us. But how quickly it occurs is not as easy for us to predict. Mike or Russ you want to add anything to that?

No, the only other thing I would add is, we have a number of accounts that continue to come on line and we've seen good growth from that historically. And we are seeing that some of the accounts that we are synching on line are not necessarily jut pediatric, but also adult and that’s something to watch for going forward.

Yeah, and also add that some of the treatment sites are using therapeutic drug monitoring. But has not been broadly incorporated into protocols, so they remain good growth opportunities for us, but they need to develop.

Okay. Great. Thank you very much.

Our next question comes from Will Tanner from FBR Capital Markets.

Thanks for taking the questions and congrats for Bruce on a great quarter. Had a question for you. Looks like you had second CBM patent review filed, I guess, for this 730 patent. And I think in your prepared remarks you mentioned that you were preparing a response and being unfamiliar with the process. Is this something that response would pertain to the first of reviewer request would be something that would pertain to both or are these going to play up potentially in parallel or sequentially. And then I had a question for Russ, if I could.

So there has been a couple of requests on the part of the end of filers for CBM related review and essentially you can think of us as responding to each of those requests. So they are separate. It's going to feel like a clump to all of you, because they were all submitted in roughly the same timeframe and I would suspect our response would be roughly in the same timeframe. And then I would expect early next year the decision on whether the PTO will review this under that CBM procedure would also come out in roughly the same timeframe. So technically separate, but not a big difference in the time periods.

And maybe then for a question asked. But is it, would there necessarily be the contemplation that you might have a different outcome from the review, I mean, granted these are business meant to patents, but is it -- I believe is possible that one of the reviews might succeed and the other one might not. So just unknown at this point.

Yeah. Unknown at this point, Will, I think the important thing for people to understand right now is this is a separate and distinct process from the litigation in the court. Remember that given the bifurcation that litigation, the distribution system related patents at least in the Roxane situation were not -- were stayed and we are not moving forward and now there is a process that’s at least kicked off. Although it itself is a long process to take a look those patents in a different jurisdiction.

Got it. And then just Russ, as it relates the number of patients, I think the average number has increased by about 150 Q over Q in the first quarter and about 350 this quarter. And I'm just trying to understand little bit better is it a little bit more of a rebound from the first quarter in terms of numbers of patients. And then I don’t recall, the company ever actually mentioning it. But I'm just curious on the average number of patients. Is that just a beginning of -- average at the beginning or the end or how is that actually calculated.

Yeah. The -- I will take the second part of the question first. It’s a pretty crude measure sort of average in the beginning and ending active patient number. That active patient number doesn’t always translate into exactly when people get prescription filled in each months and most of them are getting it monthly. It doesn’t track perfectly to commercial bottles, because it includes patients who were not -- it includes patients who get free drug under our patient assistance program. So they are not going to track up perfectly. We give that number a more to give you guys some transparency in the what fraction of the diagnosed and treated are narcolepsy patients out there or active on Xyrem to give people a sense for the number of patients getting Xyrem therapy as it might relate to your view as to the impact on payers or the healthcare system and sort of the rare nature of this important disease. But, again, it’s a relatively crude number. On the specific pattern of growth in this, we emphasized in the first quarter a little more than we usually do the growth in number of patients just to show you the disconnect we had in the first quarter between the growth in patients versus what we actually shipped in drug in the first quarter. But I don’t think we've seen any major change in that growth in patients which has continued to be fairly steady.

Okay. Thank you.

Our next question comes from John Newman from Canaccord.

Hi. Thanks for taking the question. Just two quick ones. Bruce, I may have missed heard you, but I thought that when you were talking about the meetings with the FDA, you may have mentioned that one of the things that they may have asked you to do, you will be looking to do with finding some of the data on the studies that have already been completed. I just wondered if that's the case and if you could talk a little bit more about it. The second question I had it’s kind of a broad general question. I am just curious this is more of a longer term issue, but it seems like at some point in time third quarter next year, at the latest, we will be switching over to ICD-10. I am just wondering if you think that may have any impact at all on your business, I know that's been pushed off a couple of times, so I am just curious. Thanks.

Yeah, so on the first question, which related to defibrotide and our efforts to see whether we have got a filable package, I did mention that we needed to get some data. And let me have Jeff talk about that for a second.

Sure. So when the original data package was compiled, it utilized CRF information. That covered only sometimes high level assessment. For example, did something resolve or something not resolve. There were also processes that were done again with high level documentation that FDA wanted to seek more detailed documentation on it. And so those are some examples of things that we are going out now to be able to satisfy that request.

And John on your second question, ICD-9, ICD-10 conversion process, well, I know that will be a big process for healthcare providers and much of the healthcare system. I don’t think it has any particular differential impact on Jazz Pharmaceuticals.

Great. Thank you for taking the questions.

Our next question comes from Irina Rivkind from Cantor Fitzgerald.

Hi. Thanks for taking the questions. I just wanted to follow-up on the covered business method patents issue. I am just -- since I am not familiar with this process. But what is the end goal of the generic filers in submitting these? What are they hoping to achieve if it doesn't color your litigation at all? Can you help us understand the downside risk of what happens if they prevail in this discussion at all? And then the second question is, if the FDA want you to conduct additional clinical work defibrotide for VOD, is that something that you contemplated and would go on and invest in, or would you skip that and just develop it for the other indication. Thanks.

Yeah, Irina, good questions. On the first one, the covered business method patents, I think the import here is it’s a way for the ANDA filers to contest whether these patents should have been issued. In other words, are they valid patents? This isn’t specifically about do their products infringe these patents, it's just should the patents have been issued. This is sort of a novel situation challenging the Xyrem success program in our controlled distribution system under the covered business method review process which at least if you go back and look at the history of how this came into being was specifically set up to address patents relating to financial transactions and the question of how broadly you define that and what ought to be -- what ought to fall within that I think is an interesting question, but the import just -- so all the investors potential investors out there understand it is essentially the ANDA filers asking whether these patents are valid patents or should be invalidated. On defibrotide, we're FDA to suggest that additional clinical work needed to be completed before bring in the product to market. Would we do that? I think we said when we acquired Gentium and even before the recently closed a transaction where we got the rights to defibrotide in the Americas, we said that was a potential outcome. In fact I think we said at the time we announced the Gentium deal and closed it that might be the more likely outcome that was prior to our type A meeting that we had in April of this year. So, yes, that is a possibility for us. We still think the investment we made in this product would be a great investment for our investors, but right now we're very focused on whether we can get the product to market a little bit sooner based on existing data as was the case in Europe.

Thanks.

Our next question comes from Chris Hamilton from RF Lafferty.

Sorry, my questions are already been answered. Thank you.

All right. Our next question comes from John Boris from SunTrust.

Thanks for taking the question and congratulations on the quarter. First question has to do with JZP-386. If you look at the -- I guess slowing of the metabolism of the product with potential for accumulation with Defitelio, just your thoughts around how do you ensure that you get an adequate or ideal or optimal PK/PD curve. I think you mentioned on the call you obviously want to feather-out any issues that could potentially be related to that. And then I think you're conducting the clinical in Europe just the rationale for doing it in Europe versus U.S. with the FDA -- get the FDA's blessing on conducting the trial there. And then also on the clinical relative to the (Ospec) [ph] trial that's ongoing which also uses a similar substance on the product to expand the half-life required to conduct a 58-week safety study, can you maybe give some insight into how you think the FDA might use some of the longer-term safety spec that might be required for that molecule? And then a second question just related to JZP-110, I know you mentioned that physicians are very excited about the profile, but just any thoughts you have from the Phase II data that you presented that you had an opportunity to take that to Managed Care, present the profile to Managed Care and any thoughts on how they responded to the profile? Thanks for the questions.

I'm sorry I think we have -- John could you repeat your question, we got cut off somehow.

Okay. The JZP-386 question has to do with -- can you hear me okay?

Yeah, we can hear you John.

So, no JZP-386 question just has to do with the expansion of the half-life of the drug to optimize once-daily dosing, you indicated that you certainly want to feather-out in the Phase I clinical trial the PK/PD issues that could be associated with the formulation.

Yeah. So, John let me jump in. I heard the first two parts of your question and when you hit (Ospec) [ph] we lost you.

Yeah.

On the two parts of the question and then I'll let you jump in if I missed anything. On the difference in metabolism and what we're looking for, this is the first trial in humans. We want to see what data we get. I'll remind you that in terms of what the perfect profile would be, I don't think anyone knows the answer to that question because it hasn't been studied. So, Xyrem with its relatively short half-life and it's quite nicely dosing has been extensively studied, there's good data out there. What would happen if you gave different profiles of sodium oxybate regardless of how you achieve that through duration, drug delivery, technologies, different -- completely different compounds, exactly what that would do to efficacy, to safety no one knows I think and we're certainly talking to all the experts. So, I can't really comment on what the ideal profile would be. We certainly have some ideas of what we think ought to work and how to be beneficial to patients and let's see what profile we actually get and whether early data including the PD data would suggest that we've got something interesting. In terms of the decision to do the first trial in Europe, really that was just experience. That was our goal and concerts goal, was to generate data sooner rather than later. That was the quickest path we saw to do it and so that's what we're doing. It did not reflect any particular feedback positive or negative from FDA. It was just the path we saw to get there fast.

The trial didn’t appear on clinicaltrials.gov, so did the FDA review it or not review it?

So, we have not submitted the U.S. IND at this point.

Okay. That's great. Thanks guys getting part of the question. And then just JZP-110?

On JZP-110, what did you want to know?

So, the question has to do with you certainly indicated that the profile from the Phase II clinical trial data that you presented that physicians certainly embraced it and see a highly differentiated versus for individual, have you had an opportunity to take that profile since a lot of physicians were posting their ability to prescribe two-tiered structures, take that to Managed Care and what kind of feedback if you have has Managed Care given you about the profile and JZP-110 as you're about to spend $100 million on clinical development of the compound?

Yeah. So certainly before we close the deal with Aerial, we did significant market research -- sorry for the sound of the redialing in the background. We certainly did market research to understand what the needs were out there from a patient perspective, a treator perspective, both in the narcolepsy and the OSA populations. And we believe that bringing out a product if successful that would meet the needs of the roughly half of the diagnosed and treated narcolepsy patients who can't tolerate other stimulants or don't get the benefit they need in reducing their EDS symptoms. Particularly if they've tried and failed other available agents is a pretty compelling value proposition. I think the same thing could be said of OSA patients who despite being on CPAF therapy and trying other drug therapy, similarly aren't getting the relief from the excessive daytime sleepiness that they need.

Thanks a lot for answering the questions.

Yeah. No problem.

Okay, looks like there are no further questions in queue. So, I will turn it back to Kathy for closing remarks.

Okay let me hand it back over to Kathy

Thank you. Thank you all for joining us today. We're planning to attend the Canaccord Genuity and FCR Healthcare Conferences in the third quarter and we look forward to seeing many of you there. Thanks and have a good evening.

This concludes today's conference. Thanks for your participation. You can disconnect and have a wonderful day.